Opus Genetics, Inc.
IRD
$4.11
$0.051.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -12.22% | 29.15% | 74.60% | -6.25% | -28.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.22% | 29.15% | 74.60% | -6.25% | -28.19% |
| Cost of Revenue | 11.29% | 14.42% | 15.38% | 64.43% | 78.23% |
| Gross Profit | -30.97% | -4.20% | 17.06% | -736.42% | -839.75% |
| SG&A Expenses | 8.45% | 21.18% | 72.72% | 67.83% | 39.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.15% | 17.15% | 36.86% | 65.87% | 60.34% |
| Operating Income | -18.57% | -13.28% | -26.13% | -144.53% | -198.97% |
| Income Before Tax | -82.42% | 13.80% | -150.80% | -313.50% | -419.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.42% | 13.80% | -150.82% | -313.15% | -418.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.42% | 13.80% | -150.82% | -313.15% | -418.72% |
| EBIT | -18.57% | -13.28% | -26.13% | -144.53% | -198.97% |
| EBITDA | -18.48% | -13.15% | -26.02% | -144.44% | -198.98% |
| EPS Basic | 33.42% | 60.16% | -62.23% | -234.28% | -317.85% |
| Normalized Basic EPS | -24.23% | 27.14% | 22.61% | -63.63% | -124.33% |
| EPS Diluted | 33.42% | 60.16% | -62.23% | -228.62% | -309.84% |
| Normalized Diluted EPS | -24.23% | 27.14% | 22.61% | -60.30% | -119.16% |
| Average Basic Shares Outstanding | 159.42% | 132.55% | 99.28% | 62.22% | 29.25% |
| Average Diluted Shares Outstanding | 159.42% | 132.55% | 99.28% | 60.60% | 27.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |